Generic to Namenda Oral Solution Approved
October 13, 2015 – The U.S. Food and Drug Administration granted approval to Silarx Pharmaceuticals, a subsidiary of Lannett Inc. for Memantine Oral Solution 2mg/mL. Memantine Oral Solution is a generic to Namenda Oral Solution, and is used to treat Alzheimer’s disease. IMS Health reports total sales of about $12 million for the 12 month period that ended on June 30, 2015 for Namenda Oral Solution. Silarx Pharmaceuticals has not yet announced any pricing or launch plans.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.